Kymera Therapeutics (KYMR) TD Cowen 46th Annual Health Care Conference summary

Key milestones and program updates

• Initiated two global phase 2B studies for KT-621 in atopic dermatitis (AD) and asthma, with data expected mid- and late next year, respectively.

• Phase 1 healthy volunteer study for KT-579 (IRF5 degrader) recently started, with data anticipated in the second half of the year.

• Plans to initiate a phase 1 study for a second-generation IRAK4 degrader (KT-485) in partnership with Sanofi, marking a third clinical program.

• Collaboration with Gilead to advance a CDK2 molecular glue degrader, with further disclosures expected.

STAT6/KT-621 clinical insights

• STAT6 degradation shown to robustly block IL-4 and IL-13 signaling, matching or exceeding effects of upstream biologics like dupilumab in Type 2 diseases.

• Phase 1 data demonstrated rapid onset of action and improvement in clinical endpoints such as EASI and pruritus, with continued improvement over 28 days.

• Phase 2B studies aim to provide 16-week data in AD and 12-week data in asthma, with a 52-week open-label extension for AD.

• Dose selection for phase 3 is expected to be robust due to extensive PK/PD data from phase 1 and ongoing phase 2B studies.

• Safety profile under continued evaluation, with conjunctivitis incidence to be clarified in larger, longer studies.

Market and treatment paradigm outlook

• Oral STAT6 degrader aims to address unmet needs in millions of patients lacking safe, effective oral options for Type 2 diseases.

• Goal is to position KT-621 as a first-line therapy for Type 2 diseases, offering convenience and efficacy validated by established biologics.

• Anticipates a growing market with multiple therapies, similar to the expansion seen in psoriasis.

• Combination therapies and bispecifics are seen as a future trend, with ongoing preclinical work to identify optimal partners.